Successful New Treatment For Hodgkin's Lymphoma, Reduces Long-term Risks


  Friday 17 July 2009 - 00:59:21

New research led by Cindy Schwartz, MD, of Hasbro Children's Hospital has identified a new chemotherapy regimen for pediatric Hodgkin lymphoma (HL) patients. The new treatment enhances efficacy through dose-dense drug delivery while simultaneously reducing the long-term risks presented by high cumulative dose chemotherapy. Schwartz and the researchers of the Children's Oncology Group have published their findings in the journal Blood (posted in an online first edition).

The Children's Oncology Group's Hodgkin Lymphoma Committee, led by Schwartz, director of pediatric hematology/oncology at Hasbro Children's Hospital, recognized that treatment for HL in the United States was not being treated with the most modern treatment models, in large part because it was one of the first malignancies for which a curative chemotherapy regimen was developed.

Schwartz says, "For decades, the chemotherapy regimens known as MOPP and ABVD had been the standard treatment options for these patients. However, while they yielded excellent survival rates, they often resulted in long-term effects from toxicity, including infertility, second malignancy and cardiopulmonary toxicity. With the new treatment paradigm we've developed, in essence, we've been able to cure the cancer while reducing the risk of long-term effects on our patients."

The group designed a new chemotherapy treatment known as ABVE-PC, combining six different drugs into one "dose-dense" regimen that could limit the cumulative doses of each drug below the recognized thresholds known for resulting in long-term toxicity. Their goal was to reach a rapid early response (RER) in order to further reduce cumulative therapy and to thereby increase event-free survival (EFS). They also combined the chemotherapy treatment with low dose radiation following the completion of the ABVE-PC cycles.

The treatment developed by the researchers was unique given that its focus was on early response after nine weeks, measuring to detect primary chemosensitivity – a favorable response to chemotherapy, indicating that the therapy is working. This approach differs from the traditional evaluation of the response at the end of chemotherapy. Schwartz notes that this is important, because, "This early detection allows for a reduction in therapy for those who respond well to the dose-dense treatment, and therefore, individual response can be tailored for maximum efficacy."

Schwartz, who is also a professor of pediatrics at The Warren Alpert Medical School of Brown University, believes that the study represents a new treatment model for patients with HL. She states, "Our treatment paradigm for advanced HL relied on two treatment principles: dose density enhances therapeutic efficacy and rapid early response is evidence of chemosensitivity and can serve as a basis for reduction of therapy."

The researchers conducted a trial of 216 eligible patients under 22 years of age, with intermediate or high risk HL; there were 76 females and 140 males. The median time from initial treatment to completion of the third cycle was approximately 8.7 weeks, and completion of the fifth cycle was approximately 16 weeks. While the dose densities of the chemotherapy agents exceeded those of the most commonly used regimens, cumulative doses of the chemotherapy were significantly lower, particularly in those with RER. The study was conducted at Children's Oncology Group sites between 1997 and 2001.

Schwartz says, "The results of the study indicate that through this new chemotherapy treatment we have been able to effectively deliver dose-dense chemotherapy while reducing the cumulative exposure to our patients." There are other, more immediate outcomes of the new treatment paradigm that are also of note. Schwartz also adds, "Our patients truly appreciate the rapidity of treatment. Regimens traditionally used for intermediate and advanced disease require six to eight months of chemotherapy, instead of two to three and a half months. A major benefit of this new approach is that children and young adults are able to more quickly return to school and work."

Of the 216 eligible patients, 209 were able to be evaluated for response. Of those patients, 63 percent (132 patients) showed RER, and only two of the patients showed evidence of progressive disease. RER was achieved in 67 percent of intermediate HL patients and 61 percent of high risk HL patients. The five-year event-free survival for intermediate risk HL patients was 84 percent and 85 percent for high risk HL patients. Few relapses occurred beyond three years after enrollment.

Schwartz concludes, "We have successfully achieved five-year event free survival in 84 percent of the patients and overall survival in 95 percent of our patients with this dose-dense, early-response based treatment algorithm. Only nine weeks of chemotherapy were required in 63 percent of our patients. This study has shown conclusively that the new chemotherapeutic treatment of ABVE-PC simultaneously provides high efficacy and reduces the cumulative doses of chemotherapy and radiation. We believe this represents a significant advance in the treatment of HL."

Other researchers involved in the study with Schwartz include Louis S. Constine of the University of Rochester Medical Center in Rochester, NY; Doojduen Villaluna of Children's Oncology Group - Operations Center in Arcadia, CA; Wendy B. London of Children's Oncology Group – Statistics and Data Center, University of Florida in Gainesville, FL; Robert E. Hutchison of SUNY Upstate Medical University in Syracuse, NY; Richard Sposto of Children's Hospital Los Angeles in Los Angeles CA; Steven E. Lipshultz of University of Miami Miller School of Medicine in Miami, FL; Charles S. Turner of Wake Forest University School of Medicine in Winston-Salem, NC; Pedro A. deAlarcon of St. Jude Midwest Affiliate in Peoria, IL; and Allen Chauvenet of West Virginia University HSC in Charleston, WV.

http://www.sciencedaily.com/releases/2009/07/090713160521.htm




Headlines


»Ebola virus disease update - Senegal
On 30 August 2014, Senegal’s Ministry of Public Health and Social Affairs provided WHO with details ...
»Ebola virus disease update - west Africa
A full understanding of the outbreak that will lead to improved response requires detailed analysis ...
»Ebola virus disease – Democratic Republic of Congo
On 26 August 2014, the Ministry of Health, Democratic Republic of Congo (DRC) notified the World Hea ...
»Ebola virus disease update - west Africa
Between 19 and 20 August 2014, a total of 142 new cases of Ebola virus disease (laboratory-confirmed ...


Date published: Tue, 02 Sep 2014 10:00:39
Details

»WHO issues roadmap to scale up international response to the Ebola outbreak in west Africa
WHO is issuing today a roadmap to guide and coordinate the international response to the outbreak of ...
»WHO calls for stronger action on climate-related health risks
Previously unrecognized health benefits could be realized from fast action to reduce climate change ...
»Unprecedented number of medical staff infected with Ebola
The outbreak of Ebola virus disease in west Africa is unprecedented in many ways, including the high ...
»WHO-deployed health worker receiving care after testing positive for Ebola
WHO is working to ensure an international health worker who is deployed for the Organization in Si ...


Date published: Tue, 02 Sep 2014 10:02:12
Details

»Rosuvastatin Reduces Plaque Volume in STEMI PatientsRosuvastatin Reduces Plaque Volume in STEMI Patients
Rosuvastatin 40 mg reduced plaque burden in the non-infarct-related arteries of STEMI patients ...
»Mechanical Valves in Pregnancy: Scant Progress, Big RisksMechanical Valves in Pregnancy: Scant Progress, Big Risks
Investigators said they were "shocked" by the variability in anticoagulant regimens among ...
»Brilinta Prehospital: No Reperfusion Boost, Less ThrombosisBrilinta Prehospital: No Reperfusion Boost, Less Thrombosis
UPDATED // There was no difference in markers of reflow pre-PCI in STEMI patients who got ticagrelor ...
»Infant Feeding Practices Not Linked to Childhood Food AllergiesInfant Feeding Practices Not Linked to Childhood Food Allergies
Findings from a 6-year follow-up study showed socioeconomic and atopic factors were the main predict ...


Date published: not known
Details

»Low-Fat vs. Low-Carb Diets
Source: HealthDay - Related MedlinePlus Pages: Carbohydrates, Dietary Fats, Diets, Weight Control
»Low-Carb Beats Low-Fat for Weight Loss, Heart Health
Still, experts agree there's no one-size-fits-all diet Source: HealthDay Related MedlinePlus Pages: ...
»Action-Packed TV a Threat to Your Waistline?
Viewers of fast-paced films filled up on more snacks, study found Source: HealthDay Related Medline ...
»Family Meals May Defuse Cyberbullying's Impact, Study Says
Support, communication appear to be buffers Source: HealthDay Related MedlinePlus Pages: Bullying, ...


Date published: Tue, 02 Sep 2014 11:07:45 EDT
Details

»Comedian Joan Rivers still on life support: daughter
Comedian Joan Rivers remained on life support on Tuesday after being hospitalized in serious conditi ...
»Teen Diagnosed With Cancer Looks for Cure
Laruen Bendesky was diagnosed with the disease at 14.
»Liberian doctors strike, food prices spike as West Africa struggles to contain Ebola outbreak
By James Harding Giahyue MONROVIA (Reuters) - Doctors in Liberia were out on strike on Tuesday as th ...
»U.S. missionary doctor in Liberia tests positive for Ebola: group
An American missionary doctor working in Liberia has tested positive for the Ebola virus after worki ...


Date published: not known
Details